Fungal Cell Tda3p Disruption for Recombinant Protein Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing fungal cells struggle to produce high levels of recombinant proteins efficiently due to limitations in protein folding, trafficking, and proteolytic degradation, which hinder industrial applications such as enzyme and biopharmaceutical production.
Innovation Solution
Genetic modifications in fungal cells, including disruption of the Tda3p gene and combinations of gene deletions (HDA2, HDA3, PGM2, PXA1, EMC1, VPS5, TDA3, SNC2) and overexpression of COG5 and PDI1, enhance intracellular transport and protein secretion, leading to increased recombinant protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fungal cells are used for recombinant protein production, then protein secretion capacity is limited, but increasing production levels requires overcoming folding and trafficking bottlenecks
Solution Approach 1:
The patent divides the protein production system into multiple independently modifiable components: signal peptide selection, promoter strength optimization, codon usage adjustment, and glycosylation pathway engineering. Each component can be optimized separately and combined to achieve high-level production without requiring complete system redesign
Solution Approach 2:
The patent systematically varies multiple parameters including signal peptide sequences, promoter types, codon usage patterns, and glycosylation enzyme activities. By optimizing each parameter independently and combining favorable variations, the system achieves high protein production while managing genetic modification complexity
2Productivity
If protein folding capacity is increased through chaperone overexpression, then secretion improves, but cellular resource consumption increases
Solution Approach 1:
The patent introduces chaperone genes under inducible promoters, allowing partial expression only when needed during specific growth phases. This provides sufficient folding capacity to overcome secretion bottlenecks while limiting continuous resource consumption during non-production phases
Solution Approach 2:
The patent employs chaperones and folding enzymes that are naturally regulated by the cell's own protein folding demand. The system self-adjusts resource allocation based on the actual folding burden, providing assistance only when misfolded proteins are present rather than continuous overexpression
3Productivity
If intracellular trafficking is engineered for improved secretion, then protein yield increases, but pathways become more complex and harder to control
Solution Approach 1:
The patent extracts and optimizes individual trafficking components (signal peptides, translocon interactions, Golgi sorting signals) separately from the complete trafficking pathway. By modifying only the critical extraction points rather than the entire pathway, secretion is improved while pathway complexity remains manageable
Solution Approach 2:
The patent engineers signal peptides and N-terminal sequences in advance to pre-determine protein destination and trafficking efficiency. This preliminary optimization of entry signals ensures smooth progression through the trafficking pathway without requiring complex mid-pathway regulation or control mechanisms
4Reliability
If protease activity is reduced to prevent degradation, then protein stability improves, but cellular protein turnover capability decreases
Solution Approach 1:
The patent applies protease protection locally at the secretion pathway and extracellular environment rather than globally throughout the cell. Specific protease inhibitors or protective coatings are applied only where the recombinant protein traverses, preserving cellular protein turnover functions while protecting the product
Solution Approach 2:
The patent employs sacrificial protease inhibitors or protective proteins that are inexpensive and short-lived, providing temporary protection during the secretion process. These protective elements are consumed or degraded after serving their purpose, allowing normal protease function to resume without long-term impact on cellular turnover
Data Source
AI summary
The present invention related to the provision of genetically modified fungal cells, such as yeast cells with an improved ability for producing and secreting different recombinant proteins. The improved ability is obtained by disruption in intracellular transport between the Golgi and the endosome. In particular embodiments, the disruption is achieved by downregulation or deletion of the gene encoding a Tda3p homolog. The fungal cell and method of the invention would allow for large-scale production of recombinant proteins in fungal cells.